Salarius Pharmaceuticals (SLRX)
(Real Time Quote from BATS)
$0.49 USD
-0.01 (-1.03%)
Updated Apr 29, 2024 02:26 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SLRX 0.49 -0.01(-1.03%)
Will SLRX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SLRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLRX
Salarius (SLRX) Reports Q3 Loss, Misses Revenue Estimates
SLRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SLRX
Biotech Alert: Searches spiking for these stocks today
12 Health Care Stocks Moving In Wednesday's Intraday Session
Biotech Alert: Searches spiking for these stocks today
12 Health Care Stocks Moving In Monday's Pre-Market Session
Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket